Enveric Biosciences Inc. (NASDAQ:ENVB) saw a downside of -1.40% to $2.46 after subtracting -$0.04 on Monday. The 5-day average trading volume is 141,100 shares of the company’s common stock. It has gained $2.95 in the past week and touched a new high 3 times within the past 5 days. An average of 112,165 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 171,774.
ENVB’s 1-month performance is -17.00% or -$0.54 on its low of $2.26 reached on 08/07/23. The company’s shares have touched a 52-week low of $1.30 and high of $8.54, with the stock’s rally to the 52-week high happening on 05/24/23. YTD, ENVB has achieved 18.51% or $0.35 and has reached a new high 13 times. However, the current price is down -71.14% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
ENVB stock has a beta of 1.27. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.49.
Enveric Biosciences Inc.’s quick ratio for the period ended September 29 was 3.30, with the current ratio over the same period at 3.30.
Earnings Surprise
For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -777.29% to -$4.8 million, while revenue of -$8.69 million was -81.04% off the previous quarter. Analysts expected ENVB to announce -$4 per share in earnings in its latest quarter, but it posted -$2.47, representing a 38.30% surprise. EBITDA for the quarter stood at more than -$4.75 million. ENVB stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 5.45 million, with total debt at $37040.0. Shareholders hold equity totaling $2.08 million.
Let’s look briefly at Enveric Biosciences Inc. (ENVB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 34.02% to suggest the stock is trending Neutral, with historical volatility in this time period at 80.04%.
The stock’s 5-day moving average is $2.55, reflecting a -10.99% or -$0.30 change from its current price. ENVB is currently trading -20.33% above its 20-day SMA, +42.11% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -49.48% and SMA200 by-35.54%.
Stochastic %K and %D was 16.85% and 21.40% and the average true range (ATR) pointed at 0.31. The RSI (14) points at 37.78%, while the 14-day stochastic is at 15.04% with the period’s ATR at 0.32. The stock’s 9-day MACD Oscillator is pointing at -0.07 and -0.14 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for ENVB stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ENVB as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is ENVB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $7.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Enveric Biosciences Inc. (ENVB) stock is $7.00.
